Preterm birth is a major health problem for neonates, family, country, and society in general. In our study 106 singleton pregnancies with no high risks were included to study the efficacy and safety of natural micronized progesterone in prevention of preterm labour.
Aim: To assess efficacy of natural micronized progesterone by vaginal route in prevention of preterm labour.
Material and Methods: It was a prospective study conducted at our tertiary care centre Dr. D. Y. Patil Medical College, Hospital & Research Center, Pimpri, from July 2018 to June 2019. The study population comprised of 106 pregnant females of 24 weeks to 37 weeks of gestation with singleton pregnancy with suspected risk of preterm labour who fulfilled the criteria were enrolled in the study. The total number of subjects were divided into two groups, Group A was the progesterone group (n=53) and Group B was the placebo group (n=53).
Result: It was observed in our study that the progesterone group delivered at a significantly later gestational age as compared to the placebo group [35.5±2.5 versus 33.1±2.7, p=0.001]. Also a significant rise in the birth weight of neonates was observed in the progesterone group as compared to the placebo group [2432±50 versus 1978±70, p=0.000].
Conclusion: Administration of vaginal progesterone significantly reduces the rate of preterm birth between 24-37 weeks of gestation among women with high risk factors for threatened preterm. In addition, the rates of NICU admissions, neonatal mortality and morbidity have been significantly decreased in infants of women supplemented with progesterone treatment.